Actemra (tocilizumab) Subcutaneous — Point32Health

Initial criteria

• Documented diagnosis of giant cell arteritis
• Patient age ≥ 18 years
• Prescribed by or in consultation with a rheumatologist or neurologist
• Documentation of ONE of the following: inadequate response or adverse reaction to a systemic corticosteroid OR contraindication to systemic corticosteroids OR patient is new to the plan and has been stable on the requested agent prior to enrollment